first of all every significant runup is met with a pullback . here you can see it.

at 24 it pulled back to 23, at 27 it pulled back to 25 at 29 it pulled back to 28.

now it's at 31 and it went up on MUCH lower volume, this thing has little juice left to go any higher. it will correct, stabilize and continue onward, but this current rally is overextended by the technicals.

of course this could all change with another announcement such as QE3, or other types of macro news.

Repligen Corp - RGEN - 1/3/2011 = $4.50RG1068 for Imaging of the PancreasRGEN is currently analyzing the radiographic images from our Phase 3 study of RG1068, synthetic human secretin. The goal of the study is to evaluate the sensitivity and specificity of RG1068 in combination with MRI to improve the detection of structural abnormalities of the pancreatic ducts relative to MRI alone.
There are more than 300,000 MRIs conducted in the U.S. and Europe each year that could benefit from RG1068, a potential market opportunity of over $100 million.
Results expected to be posted in Q1 2011.
They should be posting results in January or early Feb.

RG2417 for Bipolar DisorderWe have completed enrollment in our Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. The study enrolled 175 patients at 29 clinical sites within the United States. The primary objective of the Phase 2b study is to assess the efficacy of RG2417 on the symptoms of bipolar depression by demonstrating a greater improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) score of the patients receiving RG2417 when compared to placebo over an 8-week treatment period. MADRS is a standardized, rater-administered scale, which has been used for numerous drug trials in bipolar disorder. In addition, the study will assess the safety of RG2417 in patients with bipolar depression including, lack of induction of mania as measured by the Young's Mania Rating Scale. Additional secondary and exploratory objectives include improvements in the Clinical Global Impression scale, difference in MADRS scores after 8 weeks of therapy, and responder rate as defined as percent of patients with an improvement in MADRS score of greater than 50% from baseline to week 8.
Phase 2b results are expected Q1 2011.

China Health Resource - CHRI.OB - 1/3/2011 = $0.035 CHRI engages in the development, manufacture, processing, marketing, and sale of Dahurian Angelica Root (DAR), a traditional Chinese medicine and its related products in the People's Republic of China. The company?s DAR and its related products are used for the treatment of colds and cold symptoms, high blood pressure, pain, swelling, and pustule, as well as an ingredient in food, medicine, and cosmetics. Its DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate, and Fragrant Bag that are sold through regional distributors.
DAR is a common, everyday herb for many in China and is becoming more and more popular in Western Countries. The market for herbal medicine is rapidly growing on a global basis and the Company believes its herb has great potential to capitalize on the growing trend. The growth rate is currently at 20% each year in the U.S. and 30% in the European Union. China Health Resource, Inc. is focused on standardizing the Traditional Chinese Herbal Medicine and intends to expand into the $27 Billion international herbal medicine market.

There is nothing extremely exciting about the company, especial if you know nothing about their product. But it is a company that continuously makes a profit and has been growing since 2006. Their CEO's do not get a annual salary unless they exceed the previous years earnings. They also take most of their salary in stock. It should also be noted that Mr. Jiayin Wang is a former senator and has served as president and Chairman of the Board of Directors of Sichuan Yinfa Resource Development Co., Ltd, where he spearheaded the development of the standardization of pharmaceutical grade for Dahurian Angelica Root (DAR) under the Chinese State Food and Drug Administration Good Agricultural Practice of Medical Plants and Animals.CHRI.ob would be considered a monopoly in America.

I have owned this company since it was below a penny. It has been running as of late but like most pennies, it runs on news and deflates when nothing is happening. Even though I believe this company is worth its current price, I will be waiting to purchase when it gets below $ .02. This is a rare penny stock that would be considered an earnings play and a possible long term hold.
As for cons, it a company located in China but I believe Mr. Wang's influence counteracts the China factor. It is also a stock that the penny pirates like to run up. I don't believe that the recent run up was due to the penny pirates but I am not sure.

Nice rolling stock with future potential. I have a limit order for $1.95 but do not have shares yet. They have an FDA catilyst date for RIGScan CR (tumor-specific targeting agent) that should be set 1 Q of 2011, most likely in March.
Neoprobe Inc - NEOP.OB - 1/3//2011 = $2.10
- Pasted from BioRunUp.com -

Pivotal Phase 3 Clinical Trial (NEO3-09), FDA New Filing (NDA)
Lymphoseek (to detect lymph nodes in breast cancer and melanoma for potential spread of disease)
On 10/6/10, completed pre-NDA assessment with FDA, which requested data from ongoing study be included in pending NDA submission, expects to complete the study during 1Q11to support potential NDA filing by mid-2011
RIGScan CR (tumor-specific targeting agent)
On 10/21/10, submitted BLA response letter to FDA as initial step to reactivate development, to enhance the surgical treatment of solid tumor cancers, expects to file amended IND with SPA request to conduct pivotal Phase 3 program in patients with colorectal cancer, expects FDA feedback during 1Q11, will then file Phase 3 study protocol w/ SPA request
On 11/10/10, reported 3Q10 financial results, including 82.6 million (M) shares of common stock outstanding as of 8-Nov w/ stock price of $1.79 as of 19-Nov and market cap of approx. $148M
There is currently no debt on the balance sheet for NEOP.
There have been a lot of insider purchases over the last 3 months:Insider Purchases for NEOPWBB $6 dollar price target articleTaglich Brothers article - $4 (not much info)

I heard many people mentioning that they will be investing in grains & copper. As i mentioned in the original post, i know nothing about stocks, but tell me, what stock symbols are for grains? Copper? And whats your opinion?

Reply Post

“This is the official website of the Mixed Martial Arts llc. Commercial
reproduction, distribution or transmission of any part or parts of this website
or any information contained therein by any means whatsoever without the prior
written permission is not permitted.”